BAP1 and metastatic neoplasm: In contrast to the tissue samples, TS only identified mutations in GNA11 [variant allele frequency (vaf) = 0.92%] and BAP1 (vaf = 1.57%) at one plasma timepoint in 1 patient with metastatic disease 6 months after brachytherapy (Patient 09—6 months).